Skip to main content

Advertisement

Figure 4 | Alzheimer's Research & Therapy

Figure 4

From: First-in-man tau vaccine targeting structural determinants essential for pathological tau–tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model

Figure 4

Tau vaccine improves sensorimotor functions of transgenic rats. Tau vaccine–treated transgenic rats showed decreased escape latency (A) and reduced hindlimb slips (B) compared to adjuvant-treated controls. Tau vaccine–treated transgenic rats had significantly lower NeuroScale scores than adjuvant controls, which reflects an improvement of sensorimotor functions (C), *P < 0.05.

Back to article page